Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesThe efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy – a retrospective audit
European Journal of Cancer Care, 09/09/09
Ng W et al. – The optimal dose of oral ondansetron for the prevention of acute chemotherapy–induced nausea and vomiting (CINV) resulting from moderately emetogenic chemotherapy (MEC) is unknown. In this study, the use of 8 mg oral ondansetron plus 8 mg oral dexamethasone achieved control of acute emesis in 75% of all patients receiving MEC which is comparable to previously reported rates of 70–80%. The benefits of using oral pre–chemotherapy anti–emetics include reduction in the costs of drugs and nursing administration time.
Related Articles
Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy
Cancer, 10/20/09
Relevance Score: 89%
Ondansetron added to lidocaine for intravenous regional anaesthesia
European Journal of Anaesthesiology, 11/12/09
Relevance Score: 87%
Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy
Supportive Care in Cancer, 11/10/09
Relevance Score: 87%
Ropivacaine Spinal Anesthesia Is Not Antagonized by Ondansetron Pretreatment
Anesthesia & Analgesia, 10/26/09
Relevance Score: 87%
Combination therapy in the prevention of ponv after strabismus surgery in children: granisetron, ondansetron, midazolam with dexamethasone
Middle East Journal of Anesthesiology, 10/08/09
Relevance Score: 84%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial)
Annals of Oncology, 12/04/09
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
Annals of Oncology, 12/04/09
Three-dimensional (3D) Overlay Culture Models of Human Breast Cancer Reveal a Critical Sensitivity to MEK Inhibitors
Journal of Pharmacology and Experimental Therapeutics, 12/04/09
Sponsor
Article Search
Sponsor